BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling
2013; Springer Nature; Volume: 32; Issue: 3 Linguagem: Inglês
10.1038/emboj.2012.350
ISSN1460-2075
AutoresBarbara H. Chaiyachati, Anant Jani, Yisong Y. Wan, Haichang Huang, Richard A. Flavell, Tian Chi,
Tópico(s)T-cell and B-cell Immunology
ResumoArticle15 January 2013free access BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling Barbara H Chaiyachati Barbara H Chaiyachati Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Anant Jani Anant Jani Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Yisong Wan Yisong Wan Department of Immunobiology, Yale University Medical School, New Haven, CT, USAPresent address: Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Search for more papers by this author Haichang Huang Haichang Huang Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Richard Flavell Richard Flavell Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Tian Chi Corresponding Author Tian Chi Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Barbara H Chaiyachati Barbara H Chaiyachati Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Anant Jani Anant Jani Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Yisong Wan Yisong Wan Department of Immunobiology, Yale University Medical School, New Haven, CT, USAPresent address: Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA Search for more papers by this author Haichang Huang Haichang Huang Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Richard Flavell Richard Flavell Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Tian Chi Corresponding Author Tian Chi Department of Immunobiology, Yale University Medical School, New Haven, CT, USA Search for more papers by this author Author Information Barbara H Chaiyachati1, Anant Jani1,‡, Yisong Wan1,‡, Haichang Huang1, Richard Flavell1 and Tian Chi 1 1Department of Immunobiology, Yale University Medical School, New Haven, CT, USA ‡These authors contributed equally to this work *Corresponding author. Department of Immunobiology, Yale University Medical School, TCA640, 300 cedar street, New Haven, CT 06520, USA. Tel.:+1 203 785 7260; Fax:+1 203 785 4972; E-mail: [email protected] The EMBO Journal (2013)32:395-408https://doi.org/10.1038/emboj.2012.350 Present address: Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Treg activation in response to environmental cues is necessary for regulatory T cells (Tregs) to suppress inflammation, but little is known about the transcription mechanisms controlling Treg activation. We report that despite the known proinflammatory role of the chromatin-remodelling factor BRG1 in CD4 cells, deleting Brg1 in all αβ T cell lineages led to fatal inflammation, which reflected essential roles of BRG1 in Tregs. Brg1 deletion impaired Treg activation, concomitant with the onset of the inflammation. Remarkably, as the inflammation progressed, Tregs became increasingly activated, but the activation levels could not catch up with the severity of inflammation. In vitro assays indicate that BRG1 regulates a subset of TCR target genes including multiple chemokine receptor genes. Finally, using a method that can create littermates bearing either a tissue-specific point mutation or deletion, we found the BRG1 ATPase activity partially dispensable for BRG1 function. Collectively, these data suggest that BRG1 acts in part via remodelling-independent functions to sensitize Tregs to inflammatory cues, thus allowing Tregs to promptly and effectively suppress autoimmunity. Introduction FoxP3+ regulatory T cells (Tregs) are potent suppressors of inflammatory responses (Sakaguchi et al, 2008; Benoist and Mathis, 2012). Precise regulation of Treg activity is essential for preventing autoimmunity while simultaneously permitting adequate immune response to pathogens. Various Treg properties are subject to regulation, including activation, migration, homoeostasis and functional specialization (Campbell and Koch, 2011; Yamaguchi et al, 2011; Josefowicz et al, 2012). This regulation is first suggested by the observation that normal mice harbour both naïve-like and effector/memory-like Treg subsets, the former homing to secondary lymphoid organs while the latter express activation markers (such as CD69 and ICOS) and traffic to non-lymphoid tissues (Huehn et al, 2004). Tregs produced from the thymus are all naïve-like, but a subset of them quickly acquires the effector/memory-like phenotype after entering secondary lymphoid organs, which occurs as a result of encounters with self-antigens and is presumably essential for peripheral tolerance (Lee et al, 2007). Tregs are subject to an additional layer of regulation in the presence of overt inflammation (due to, e.g., pathogen infection or organ transplant), which can involve Treg activation, expansion, differentiation and trafficking (Belkaid et al, 2002; Suffia et al, 2006; Belkaid and Tarbell, 2009; Zhang et al, 2009). Treg activation is crucial for Treg function both in vitro and in vivo (Takahashi et al, 1998; Thornton and Shevach, 1998; Park et al, 2010). The transcription programs controlling such intricate Treg properties are under intense investigation. The best-defined transcription factor in Tregs is FOXP3, which is required for Treg development, proliferation, suppressor function and lineage stability; loss-of-function mutations in FoxP3 results in early-onset, aggressive, lethal inflammation in both humans and mice (Rudensky, 2011). FOXP3 acts by stabilizing and amplifying the expression of immunosuppressive genes while repressing proinflammatory genes. A number of other sequence-specific transcription factors have also been implicated in Treg development and function. These include the factors that promote FoxP3 expression during development or homoeostasis (such as FOXO, NF-kb, GATA3 and FOXP3 itself) and those that direct Treg functional specialization in response to inflammatory cues (such as T-BET, IRF4 and STAT3 selectively required for Tregs to suppress Th1-, Th2- and Th17-type inflammation, respectively) (Chaudhry et al, 2009; Koch et al, 2009; Long et al, 2009; Zheng et al, 2009; Kerdiles et al, 2010; Ouyang et al, 2010; Zheng et al, 2010; Ouyang and Li, 2011; Wang et al, 2011). Much less is known regarding the transcription programme that controls Treg activation, even though Treg activation is essential for Treg function. Available data indicate that the activation mechanisms in Tregs are divergent from conventional CD4 cells. For example, contrary to conventional CD4 cells, Tregs do not proliferate upon TCR stimulation alone; IL-2 is additionally required (Campbell and Ziegler, 2007). Furthermore, while TCR stimulation of Tregs is obligatory for Treg-suppressive function in vitro, pharmacological inhibition of multiple signal transduction pathways known to be downstream of TCR in conventional CD4 cells fails to disable Tregs (Hagness et al, 2012). Furthermore, in conventional CD4 cells, NFAT is localized in the cytoplasm in resting cells and moves to the nucleus upon TCR stimulation, where it drives T-cell activation and proliferation. In contrast, in Tregs, a fraction of NFAT is constitutively nuclear, and calcium influx is dispensable for Treg proliferation induced by TCR/IL-2 stimulation (Li et al, 2012a). Finally, we found that resting Tregs expressed detectable amounts of c-Fos and c-Jun messages, which was unexpectedly downregulated within 2 h following TCR stimulation (unpublished). To regulate gene expression, sequence-specific transcription factors must act in conjunction with enzymes that modulate chromatin structure. Such enzymes fall into two major classes: histone-modifying enzymes that covalently modify histones to alter chromatin structure, and ATP-dependent chromatin remodellers that use energy of ATP hydrolysis to physically disrupt histone–DNA contact, thus loosening or moving nucleosomes (Narlikar et al, 2002; Clapier and Cairns, 2009). The prototypical mammalian chromatin remodeler is the BAF chromatin-remodelling complex related to the yeast Swi/Snf complex (Wang, 2003; Chi, 2004). The BAF complex contains ∼10 subunits, including the catalytic subunit BRG1. BRG1 is widely expressed, but its function is tissue-specific. For example, whereas BRG1 regulates the survival and CD4/CD8 expression in early thymocytes (Chi et al, 2002, 2003; Gebuhr et al, 2003; Jani et al, 2008), it promotes Th1/Th2 differentiation of conventional CD4 cells (Zhang and Boothby, 2006; Wurster and Pazin, 2008). Genome-wide mapping of BRG1-binding sites in conventional CD4 cells demonstrates that BRG1 often binds enhancer/promoters, and the binding patterns at some target genes vary according to the status of T-cell activation and/or effector lineage differentiation (De et al, 2011). Interestingly, using a genetic strategy that can produce littermates bearing either thymocyte-specific Brg1 deletion or a BRG1 ATPase point mutation (PM) that abolishes its chromatin-remodelling activity, we found that the BRG1 PM cannot fully recapitulate the defects in early T-cell development caused by Brg1 deletion. The data indicate that BRG1 harbours remodelling-independent activities sufficient for regulating the expression of some target genes in early thymocytes, but it is unclear whether such activities are of general importance (Jani et al, 2008). The role of BRG1 in Tregs is unknown. Here we report that BRG1 is essential for efficient Treg activation, and that BRG1 function is partially independent of its ATPase activity. Results Deletion of Brg1 from all αβ T-cell lineages results in late-onset inflammation in a fraction of mice To study the role of Brg1 in T cells, we generated Brg1F/F; CD4Cre mice. PCR analysis confirmed that Brg1 was deleted in DP and peripheral T cells (not shown). Brg1 deletion did not grossly perturb T-cell development (Supplementary Figure S1) and young adults did not show any obvious phenotype. However, ∼20% of the mice eventually developed overt inflammation (by ∼5 months of age) characterized by rectal prolapse, colonic oedema, lymphadenopathy, splenomegaly and perivascular infiltration in multiple organs including liver and kidney (Figure 1A and B). In addition, in these mice, total lymphocyte count approximately doubled in peripheral lymph nodes (PLN) largely due to accumulation of B cells (Figure 1C, column 1), while the abundance of CD4 relative to CD8 cells remained unaltered (Figure 1C, column 2). B cells also accumulated in the spleen, albeit to a less extent (Figure 1C, column 3). Finally, effector/memory CD4 cells accumulated in the periphery and CD4 cells overproduced IFN-γ but not IL-4 or IL-17 (Figure 1D). By ∼7 months of age, these 20% of mice either died spontaneously or were euthanized for humane concerns. In contrast, the remaining 80% of the mice remained healthy. Figure 1.Phenotype of Brg1F/F; CD4Cre mice (KO) versus Brg1-sufficient littermates (WT). (A–D) Inflammatory disorder in ∼5-month-old KO mice. (A) Gross appearance of colon, peripheral LN and spleen. (B) H & E staining of tissue sections of colon, liver and kidney. Arrows indicate foci of cell infiltration. (C) Cell composition of LN and spleen. Cells were stained for CD4, CD8 and TCR before TCR+ cells were analysed for CD4/CD8 expression. The numbers in red within the plots are total cellularity (+/− s.d.) averaged from at least three mice. (D) Lymphocytes were either stained for CD4, CD44 and CD62L cells to quantify the abundance of effector/memory (CD44high CD62Llow) CD4 cells (top left), or stimulated with PMA and ionomycin for 4–6 h for the analysis of cytokine induction in CD4 cells (top right). The scatter plot at the bottom summarizes the data from splenic CD4 cells. (E–G) No apparent defects in Brg1 KO Tregs. (E) Treg frequencies in ∼5-month-old mice. The data are averaged from five mice. (F) Expression of Treg markers in ∼5-month-old mice. (G) Brg1 KO did not impair the ability of Tregs to suppress CD4 cell proliferation in vitro. Tregs were isolated from ∼4-week-old Brg1F/F; CD4Cre mice. Naïve CD4 cells from WT mice were co-cultured with equal numbers of or five-fold less Tregs in the presence of mitogenic stimuli. Proliferation of CD4 cells was measured by H3-thymidine incorporation. Data are averaged from five independent experiments. Download figure Download PowerPoint Brg1 is not essential for Treg development or in vitro suppression Given the known roles of Brg1 in promoting Th1/Th2 differentiation, it was unexpected that Brg1 deletion in T cells would lead to hyperinflammation rather than immune deficiency. We reasoned that since Brg1 deletion in DP cells using the CD4Cre transgene depleted BRG1 not only in conventional T cells, which would impair immune responses, but also in Tregs, which might impair Treg development/function and enhance the immune responses, Brg1 deletion in all T cells might have conflicting effects on inflammation, with the balance tipped towards hyperinflammation in some mice. Thus, we examined Tregs in Brg1F/F; CD4Cre mice. Tregs were present in normal numbers and expressed normal levels of FOXP3, CD25, GITR and CTLA4 (Figure 1E and F), suggesting Brg1 was dispensable for Treg development. To determine whether Brg1 KO Tregs were functionally defective, we measured the ability of Tregs to inhibit the proliferation of CD4 cells in vitro. To avoid potential confounding effects of hyperinflammation on Treg function, Brg1 KO Tregs were isolated from ∼4-week-old Brg1F/F; CD4Cre mice lacking overt inflammation. Tregs were co-cultured with naïve WT CD4 cells in the presence of irradiated antigen-presenting cells and anti-CD3, and the proliferation measured by H3-thymidine incorporation. As expected, Tregs did not proliferate while CD4 cells showed robust proliferation, incorporating high amounts (∼5000, c.p.m.) of H3-thymidine, which was inhibited by WT Tregs in a dose-dependent manner (Figure 1G, white bars). Importantly, Brg1 KO Tregs were even more effective than WT Tregs in suppressing CD4 cell proliferation in this assay (Figure 1G, black bars), indicating the inflammation in vivo is not due to a defect in Treg-suppressive function as measured by this assay. Thus, despite the inflammation in Brg1F/F; CD4Cre mice, there was no obvious defect in Treg development or function. Treg-specific Brg1 deletion produces early-onset, aggressive, fatal inflammation To further explore the mechanism of autoimmunity in Brg1F/F; CD4Cre mice, we deleted Brg1 selectively in Tregs. Without the antagonizing effects of Brg1 deletion in conventional effector T cells, the Treg-specific deletion should produce a more severe phenotype than that in Brg1F/F; CD4Cre mice, if the inflammation in Brg1F/F; CD4Cre mice indeed reflected a role of Brg1 in Tregs. To delete Brg1 in Tregs, we crossed Brg1F/F mice to a Cre-deleter line bearing an Ires-Cre-YFP cassette knocked into the 3′ UTR of the FoxP3 locus, which causes Cre-YFP fusion protein to be co-expressed with FOXP3 (Rubtsov et al, 2008). Since FoxP3 is located on the X-chromosome, which undergoes random inactivation, Brg1 was deleted in all Tregs only in Brg1F/F; FoxP3YFP-Cre hemizygous males and Brg1F/F; FoxP3YFP-Cre/YFP-Cre homozygous females (termed 'KO' thereafter), whereas the Brg1F/F;FoxP3YFP-Cre/YFP-Cre/+ heterozygous females were mosaic, containing not only YFP+ but also YFP− Tregs and were thus healthy (see further). We found that the KO mice invariably developed an early-onset, aggressive, fatal inflammatory disorder more severe than that in Brg1F/F; CD4Cre mice and reminiscent of that seen in Scurfy mice bearing a germline FoxP3 mutation that blocks Treg development (Godfrey et al, 1991). Specifically, starting as early as 2 weeks of age, the mice frequently began to show appreciable runting, blepharitis, alopecia, increased abdominal girth, palpable lymph nodes and pale foot pads, which became increasingly obvious and penetrant with age. Adult mice were severely runted (Figure 2A and D) and 50% of mice died within 50 days after birth, the mortality rate reaching nearly 100% by 200 days (Figure 2C), which is less severe than scurfy mice that died within 3–6 weeks of age in our hands. Liver necrosis was dramatic (Figure 2A), as was lymph nodes and spleen enlargement (Figure 2A and E). Erythrocytes were visibly depleted in both bone marrow and blood, consistent with profound anaemia (Figure 2A and F). Perivascular cellular infiltration was apparent in multiple tissues (Figure 2B) with concordant accumulation of CD8 as well as B and CD4 cells in the liver (Figure 2G, right). In addition, CD8 cells accumulated in the spleen (Figure 2G, middle). The thymi were extremely small and depleted of DP cells, presumably due to distress-induced apoptosis (Figure 2H). Effector/memory CD4 cells dramatically accumulated in spleen and lymph nodes (Figure 3A and C). The CD4 cells of any single mouse overproduced one or more of the three lineage-specific cytokines (IFN-γ, IL-4 and IL-17), which suggests that Brg1 deficiency in Tregs impaired the function of each of the three effector Treg subsets, thus pointing to a fundamental role of Brg1 in Treg function (Figure 3B and C). Finally, CD4 cells were hyperproliferative (Figure 4E). These data confirm that Brg1 is essential for Treg-mediated immune suppression. Figure 2.Effects of Treg-specific Brg1 deletion. Brg1F/F; FoxP3YFP-Cre males and Brg1F/F; FoxP3YFP-Cre/YFP-Cre females (KO) were compared with Brg1-sufficient, gender-matched littermates (WT) that carried one or two functional Brg alleles. (A, B) Gross anatomy (A) and histology (B) of ∼30-day-old males. The ears in (A) were from males different from that shown at the top of panel A. The white and red arrows in (A) indicate necrotic spots on liver and enlarge spleen, respectively. (C) Survival of males. (D) Body weight of 40-day-old males. The symbols represent individual mice. (E–H) The weight of spleen relative to that of the whole body (E), haematocrit (F), lymphocyte cellularity (G) and thymocyte composition (H) in ∼30-day-old males. In H, thymocytes were stained with TCRβ, CD4 and CD8 antibodies before the TCR−/lo and TCRhi subsets were analysed for CD4/CD8 expression. Download figure Download PowerPoint Figure 3.CD4 cells in 25- to 50-day-old KO mice. (A) Accumulation of effector memory (CD44high CD62Llow) CD4 cells in LN and spleen. (B) Enhanced cytokine induction in CD4 cells stimulated with ionomycin (1 μM) and PMA (1 ng/ml) for 5 h. (C) Summary of data from experiments represented in (A) and (B). Download figure Download PowerPoint Figure 4.Tregs in 25- to 50-day-old KO mice. (A) Normal FOXP3 expression. Cells were stained for CD4 and FoxP3 before analysis. (B) KO Tregs did not express IFN-γ in hyperinflammatory environment whereas CD4 cells from the same mouse overproduced IFN-γ as expected (right). Cells were stimulated with ionomycin (1 μM) and PMA (1 ng/ml) for 5 h before staining for intracellular FOXP3 and IFN-γ. (C) Absolute numbers of Tregs (left) and their abundance relative to CD4 cells (right) in various organs. The inset is a blown-up view of the cellularity in the liver. (D) Normal viability. Splenic lymphocytes were stained with CD4APC and annexin–PE before analysis of annexin expression in CD4+YFP+ Tregs. (E) Proliferation. Mice were exposed to the BrdU analogue EdU for 3 days. Splenic conventional CD4 cells (CD4) and Tregs were FACS-purified based on YFP expression before analysis of EdU incorporation. (F) Expression of activation markers (including chemokine receptors) in splenic Tregs. Mice were separated into two age groups (25–29 versus 30–50 days old) based on distinct mortality rates (see Figure 2C). Download figure Download PowerPoint Brg1 deletion impairs Treg activation in response to self-antigens: analysis of Tregs at different stages of inflammation in mice with Treg-specific Brg1 deletion We next investigated the mechanisms whereby Brg1 promotes Treg function. We first analysed Tregs in 25–50-day-old Brg1F/F; FoxP3YFP-Cre males, which had developed overt inflammation. We found that Brg1 KO Tregs expressed normal levels of FOXP3 (Figure 4A), lacked aberrant expression of proinflammatory cytokine IFN-γ, IL-4 or IL-17, were not converted to conventional CD4 cells (Figure 4B; data unpublished), and their numbers and frequencies in lymphoid organs were comparable to that in the littermate controls (Figure 4C). Interestingly, there was a two-fold increase in total Treg numbers in the liver, suggesting some Brg1 KO Tregs had migrated to the liver in response to inflammation (Figure 4C, left, inset) although the proportions of the Tregs relative to conventional CD4 cells remained unaltered (Figure 4C, right) due to the aforementioned accumulation of conventional CD4 cells (Figure 2G, right). Finally, Brg1 deficiency did not affect Treg viability (Figure 4D) although Treg proliferation seemed marginally (albeit statistically insignificantly) impaired (from 5.3±3.1 in WT to 2.8±1.4 in KO, P=0.07; Figure 4E). These data do not reveal a clear defect in Brg1 KO Treg. As Treg activation is essential for Treg function, we examined the activation status of Brg1 KO Tregs by analysing effector/memory-like Tregs (CD44highCD62Llow) and multiple activation markers (CD103, CXCR3, CCR2, ICOS and CD69). Given the severe inflammation, the mutant mice should harbour more activated Tregs, and such cells should become more abundant with age. We therefore analysed both young (day 20–29) and old (day 30–50) mice; both groups had severe inflammation but the young mice were mostly viable while the old ones showed a high mortality rate (Figure 2C). As compared with WT mice, there was no increase in the frequencies of effector/memory-like or CD69+ Tregs even in the old KO mice, suggesting that Brg1 deficiency indeed impaired Treg activation (Figure 4F). However, remaining markers (CD103, CCR2, CXCR3 and ICOS) were all elevated in the KO mice relative to the WT mice (Figure 4F; this upregulation of trafficking molecules is consistent with the aforementioned increase in Treg abundance in the liver shown in Figure 4C, left). The data, however, are difficult to interpret because of the severe inflammation in the KO mice; it is possible that without the inflammation, marker expression might be below the WT level, which would reveal a role of BRG1 in Treg activation. To address this, we analysed Tregs in very young (∼10-day-old) Brg1 KO mice (Brg1F/F; FoxP3YFP-Cre males and Brg1F/F; FoxP3YFP-Cre/YFP-Cre females), where outward manifestations of inflammation were unappreciable, although hepatic cellular infiltration (Figure 5A and B) and splenic accumulation of effector/memory CD4 cells (Figure 5C) had emerged. Remarkably, despite the weak inflammation, the activation markers in the Brg1 KO Tregs were indeed expressed below the WT level (Figure 5D). Curiously, the 'effector/memory-like' (CD44HighCD62Llow) Tregs were only marginally decreased. However, these cells in the 10-day-old mice were paradoxically more abundant than in 25–50-day-old mice (∼60–70% versus ∼40%; compare Figure 5D with 4F), suggesting that in 10-day-old mice, the CD44HighCD62Llow Treg pool was heavily contaminated with non-effector/memory-like cells, which might have obscured the depletion of effector/memory-like cells in the KO mice. Finally, in agreement with defective expression of inflammatory chemokine receptors, Treg trafficking to inflamed liver seemed impaired in these mice: despite the onset of hepatitis as manifested by the cellular infiltration in the liver, hepatic Treg numbers in these mice were not increased (2300±500 compared with 2900±600 in WT mice; Figure 5E, top) and so the abundance of hepatic Tregs relative to total CD4 cells was decreased due to infiltration/proliferation of conventional CD4 cells (from 16.6±2.2 down to 5.1±0.2%; Figure 5E, bottom). Thus, in the very young KO mice, despite the mild inflammation, Tregs were hypoactivated relative to that in the WT mice, demonstrating a role of BRG1 in Treg activation. Figure 5.Treg hypoactivation in ∼10-day-old KO mice. (A) Cell infiltration (arrow) in liver in Brg1 KO mice. (B) Numbers of lymphocytes recovered from the liver. The inset is a blown-up view of the CD4 and CD8 cellularity. (C) Accumulation of effector/memory CD4 cells in the spleen. A representative experiment was shown at the top, and the data summarized at the bottom. (D) Defective Treg activation. Shown are the frequencies of splenic Tregs expressing various surface markers. (E) Relative depletion of Tregs in the liver. Download figure Download PowerPoint Defective Treg activation revealed in mosaic females To corroborate the above data, we examined the mosaic Brg1F/F; FoxP3YFP-Cre/+ females. These mice were healthy, harbouring both YFP+ and YFP− Tregs (Figure 6A, left), with Brg1 specifically deleted in the YFP+ subset (Figure 6B), thus allowing for comparison of WT and KO Tregs under identical, noninflammatory conditions. Figure 6.Tregs in mosaic Brg1F/F; FoxP3YFP-Cre/+ (F/F) adult females and the littermate control Brg1F/+; FoxP3YFP-Cre/+ (F/+) females. (A) YFP versus CD25 expression in total CD4 cells. (B) qPCR measuring Brg1F abundance in Tregs. (C) Viability of YFP+ Tregs. Splenic Tregs were stained for CD4 and annexin before analysis of annexin expression in CD4+YFP+ Tregs. (D–F) Abundance (D), proliferation (E) and activation (F) of YFP− versus YFP+ Tregs. Download figure Download PowerPoint We analysed Brg1F/F; FoxP3YFP-Cre/+ females together with the heterozygous Brg1F/+; FoxP3YFP-Cre/+ female littermate controls. We found that Brg1 deletion in Brg1F/F; FoxP3YFP-Cre/+ females did not affect Treg viability (Figure 6C) but slightly depleted Tregs relative to the YFP− subset (Figure 6D, groups 3 versus 4). This depletion is consistent with impaired Treg homeostatic proliferation, as evidenced by a moderate decrease in EdU incorporation (Figure 6E). Importantly, Brg1 deletion impaired effector/memory-like Treg production and induction of all the activation markers (Figure 6F). This activation defect may also explain the impaired homoeostatic proliferation, as the latter is presumably dependent on TCR signalling and hence activation. Interestingly, in Brg1F/+; FoxP3YFP-Cre/+ females, Treg proliferation (Figure 6E) and induction of some markers (CD69 and ICOS; Figure 6F) seemed marginally impaired in YFP+ Tregs as compared with the YFP− Treg subset, although the differences were statistically insignificant. Since the YFP+ cells in these mice contained only one copy of Brg1, the data raised the possibility that both copies of Brg1 is required for optimal Treg activation. These data reinforce the notion that BRG1 promotes Treg activation in response to self-antigens. Defective Treg activation during ConA-induced inflammation We next determined whether BRG1 also promotes Treg activation in response to pathological inflammatory cues, using as a model system concanavalin A (Con A)-induced hepatitis (Tiegs, 2007). Con A triggers acute Th1-type hepatitis and induces the expression of multiple CXCR3 ligands in the liver. In response, Tregs quickly express CXCR3 (perhaps due to stimulation by Con A in combination with IFN-γ) and migrate to the liver to restrain the inflammation (Erhardt et al, 2011). Since Brg1 KO Tregs must not be exposed to inflammation prior to Con A injection, we performed the experiments in Brg1F/F; FoxP3YFP-Cre/+ females. In the experiments, the YFP− (WT) Tregs could theoretically serve as an internal control for YFP+, Brg1-deficient Tregs. However, as the former cells were YFP−FoxP3+, a combination of FOXP3 staining and YFP fluorescence was needed for their identification, which proved technically difficult especially for the cells isolated from the liver (not shown). One option would be to use CD25 to identify the YFP− Tregs. However, CD25 is also expressed in conventional CD4 cells where its expression is presumably subject to influences by Con A, thus confounding data interpretation. We therefore used the Brg1F/+FoxP3YFP-Cre/+ female littermates as controls, as these mice contained Brg1-sufficient Tregs marked by YFP, which bypassed the need for FOXP3 or CD25 staining. Our analysis was focused on CXCR3+ Tregs, the central player in this hepatitis model (Erhardt et al, 2011). As expected from Figure 6F, prior to Con A injection, the frequencies of Brg1 KO YFP+ CXCR3+ Tregs were ∼2-fold lower in Brg1F/F; FoxP3YFP-Cre/+ mosaic females than the WT counterpart in the littermate controls (Figure 7A, left and Figure 7B, top). We then injected Con A and analysed CXCR3 induction 48 h thereafter, at a time when Treg numbers in the liver had peaked (Supplementary Figure S2). Before Con A injection, CXCR3 was expressed in ∼21% of YFP+ WT Tregs in the spleen, and
Referência(s)